E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent metastatic melanoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027481 |
E.1.2 | Term | Metastatic melanoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy and safety of treatment with Allovectin-7® versus treatment with DTIC or TMZ in subjects with recurrent metastatic melanoma. |
|
E.2.2 | Secondary objectives of the trial |
To compare the safety/tolerability of treatment with Allovectin-7® versus treatment with DTIC or TMZ in subjects with recurrent metastatic melanoma. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Allovectin-7® Immunology Sub-study: The objective of this sub-study is to retrospectively determine specific immune markers and assess their correlation with the efficacy of Allovectin-7® and to explore the possible mechanisms of action of Allovectin-7® in humans |
|
E.3 | Principal inclusion criteria |
- Able and willing to provide informed consent and sign the informed consent form - Age 18 or more years - ECOG performance status of 0 or 1 - Histologically confirmed recurrent metastatic melanoma, which may have received primary surgical resection, adjuvant therapy, and/or biotherapy - At least one injectable lesion (cutaneous, subcutaneous, or nodal lesion) ≥1 cm2 and ≤25 cm2. Lesions between 25 cm2 and 100 cm2 are not injected but may be followed as target lesions - LDH within normal limits - Serum creatinine ≤ 2.0 mg/dL - Platelet count 100,000/mm3 or more - White blood cell count 2500/mm3 or more - Male and female subjects of child bearing potential must agree to use an effective method of contraception - Negative pregnancy test for women of child bearing potential |
|
E.4 | Principal exclusion criteria |
- Prior cytotoxic chemotherapy for malignant melanoma - Prior Allovectin-7® injection(s) - Any lesion 100 cm2 or more - History of visceral metastasis, M1c, other than lung (M1b not excluded) - Surgery as a curative option - Radiation therapy, immunosuppressive therapy or biologic therapy within four weeks prior to trial entry - Major surgery within two weeks prior to trial entry - Known positive HIV serology - Other malignancy not currently in remission or unlikely to have been cured with prior therapy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or low grade prostate cancer) - Concurrent immunosuppressive therapy, anticancer therapy or investigational treatment - Active autoimmune disease requiring immunosuppressive or other therapies; e.g. Hashimoto’s Disease, Systemic Lupus Erythematosus, autoimmune hepatitis, Wegner’s granulomatosis, etc. - Significant psychiatric disorders that would make compliance with the protocol difficult or would compromise ability to give informed consent - Female subjects who are pregnant or lactating
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To compare the overall response rate at ≥24 weeks after randomization in the Allovectin-7® arm versus the control (DTIC/TMZ) arm. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of this trial is defined as the completion of the last visit by the last enrolled subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |